Research shows that fatty liver disease (MASH) significantly increases the risk of atrial fibrillation, the most common type of irregular heartbeat. According to Gram Research analysis, a protein called osteopontin released by damaged liver cells triggers inflammation in the heart that causes rhythm problems. In a study of over 15,000 people, those with liver scarring had substantially higher rates of atrial fibrillation, and blocking osteopontin in mice completely prevented heart rhythm problems, suggesting a new treatment approach.
Scientists discovered a surprising connection between a fatty liver disease called MASH and irregular heartbeats (atrial fibrillation). According to Gram Research analysis, the liver releases a protein called osteopontin when it’s damaged, which travels through the bloodstream and triggers inflammation in the heart. Using both human patient data and mouse studies, researchers found that blocking this protein or stopping the inflammatory response prevented heart rhythm problems. This discovery could lead to new treatments for people with liver disease who are at risk for dangerous heart arrhythmias.
Key Statistics
A 2026 research study analyzing the ARIC cohort of over 15,000 participants found that people with intermediate to high liver fibrosis scores had significantly elevated risk of atrial fibrillation compared to those with low fibrosis scores.
In mice with metabolic dysfunction-associated steatohepatitis (MASH), blocking the liver protein osteopontin or its receptor CD44 completely prevented pacing-induced atrial fibrillation and atrial remodeling, according to 2026 research published on bioRxiv.
A 2026 study identified that osteopontin, a hepatokine secreted by damaged liver cells, promotes the recruitment of inflammatory macrophages to the heart atria, triggering gasdermin D activation and proarrhythmic remodeling in MASH models.
Neutralizing circulating osteopontin with antibodies or deleting the Spp1 gene in hepatocytes prevented MASH-induced atrial fibrillation susceptibility in mice, according to 2026 research, suggesting osteopontin as a therapeutic target for liver disease-related arrhythmias.
The Quick Take
- What they studied: Whether a damaged, fatty liver causes irregular heartbeats and what protein is responsible for the connection
- Who participated: Over 15,000 people from the ARIC study (a long-term health study) plus laboratory mice with fatty liver disease
- Key finding: People with signs of liver scarring had significantly higher rates of atrial fibrillation, and a liver protein called osteopontin was the key culprit triggering heart inflammation
- What it means for you: If you have fatty liver disease, your doctor may want to monitor your heart more closely. New treatments targeting the osteopontin protein could eventually prevent heart rhythm problems in these patients, though these therapies are still in early development
The Research Details
This research combined two approaches to find answers. First, scientists studied real patient data from the ARIC study, tracking over 15,000 people to see if those with liver scarring developed more heart rhythm problems. Second, they created mice with fatty liver disease in a laboratory to understand exactly how the liver damage causes heart problems.
In the mouse studies, researchers used advanced techniques like genetic engineering to turn off specific proteins and see what happened. They measured heart electrical activity, looked at heart tissue under microscopes, and analyzed which cells were activated during the disease process. This allowed them to trace the exact pathway from liver damage to heart problems.
The researchers also studied blood samples and heart tissue to identify which proteins were being released by the damaged liver and how they affected heart cells. This detective work revealed that a protein called osteopontin was the main messenger carrying the harmful signal from liver to heart.
This research matters because it explains why people with liver disease have more heart problems. Instead of just knowing there’s a connection, scientists now understand the actual mechanism—the specific protein and cells involved. This knowledge opens the door to developing targeted treatments that could block just this harmful pathway without affecting other body systems.
This study is strong because it used multiple types of evidence: real patient data from a large, well-established study plus controlled laboratory experiments. The researchers used cutting-edge techniques like genetic deletion and single-cell analysis to prove cause-and-effect relationships. However, the mouse studies need to be confirmed in human trials before new treatments can be used in patients. The study was published as a preprint, meaning it hasn’t yet gone through the full peer-review process that published journal articles undergo.
What the Results Show
In the ARIC study of real patients, people with signs of liver scarring (measured by the FIB-4 index) had significantly higher rates of atrial fibrillation compared to those with healthy livers. The risk increased with the severity of liver damage.
In mice with fatty liver disease, researchers could trigger irregular heartbeats more easily than in healthy mice. The diseased mice also showed enlarged atria (the upper heart chambers) and scarring in the heart tissue, even though their lower heart chambers worked normally.
When scientists blocked the osteopontin protein—either by deleting the gene that makes it in liver cells or by using antibodies to neutralize it in the bloodstream—the mice no longer developed heart rhythm problems. This proved that osteopontin was the critical link between liver disease and heart arrhythmias.
The research revealed that osteopontin triggers immune cells called macrophages to invade the heart and cause inflammation. When researchers blocked either the osteopontin receptor (CD44) or a downstream inflammatory protein (GSDMD), they prevented both the immune cell invasion and the heart rhythm problems.
The study identified that osteopontin levels in the blood could potentially serve as a warning sign for which liver disease patients are at highest risk for heart rhythm problems. The inflammatory macrophages that invade the heart have specific markers (TGFBR1+) that distinguish them from other immune cells, suggesting they could be targeted specifically without affecting the immune system elsewhere. The research also showed that heart enlargement and scarring occurred independently of any problems with the lower heart chambers, indicating a specific vulnerability of the upper chambers to this liver-derived inflammation.
Previous research knew that fatty liver disease and heart rhythm problems often occur together, but the cause was unclear. This study advances the field by identifying the specific protein (osteopontin) and the exact inflammatory pathway responsible. It also explains why some people with liver disease develop heart problems while others don’t—those with higher osteopontin levels appear to be at greater risk. The finding that blocking osteopontin prevents heart problems in mice is novel and suggests a new treatment direction that previous research hadn’t explored.
The most important limitation is that these findings come from mouse studies and human observation data, not from human treatment trials. Mice don’t always respond to treatments the same way humans do. The human data shows correlation (liver disease and heart problems occur together) but doesn’t prove that the liver disease directly causes the heart problems—other shared risk factors could be involved. The study was published as a preprint, meaning it hasn’t yet been reviewed by independent experts in the field. Additionally, the exact mechanisms might differ between mice and humans, and the osteopontin pathway might not be equally important in all patients.
The Bottom Line
If you have fatty liver disease, discuss heart health monitoring with your doctor (moderate confidence). Don’t wait for osteopontin-blocking drugs to become available—focus on proven liver disease treatments like weight loss, exercise, and managing blood sugar and cholesterol (high confidence). Future patients may benefit from osteopontin-targeting therapies once they’re developed and tested in humans (low confidence, experimental stage).
People with MASH (metabolic dysfunction-associated steatohepatitis) or other fatty liver diseases should pay attention to this research. Those with family history of both liver disease and heart rhythm problems should be especially vigilant. Cardiologists and liver specialists should consider this connection when treating patients with both conditions. This research is less immediately relevant for people with healthy livers.
If you have liver disease, heart rhythm problems can develop over months to years, so monitoring is important now. If osteopontin-blocking treatments are developed, they would likely take 5-10 years to complete human trials and reach patients. Benefits from lifestyle changes (weight loss, exercise) for liver health can appear within weeks to months.
Frequently Asked Questions
Can fatty liver disease cause heart rhythm problems?
Yes. Research shows that metabolic dysfunction-associated steatohepatitis (MASH) increases atrial fibrillation risk. A liver protein called osteopontin released during liver damage triggers inflammation in the heart that disrupts normal rhythm. People with liver scarring had significantly higher atrial fibrillation rates in a study of 15,000+ patients.
What is osteopontin and why does it matter for my heart?
Osteopontin is a protein your liver releases when it’s damaged by fatty disease. It travels through your bloodstream and activates inflammatory immune cells in your heart, causing the upper chambers to enlarge and scar, leading to irregular heartbeats. Blocking osteopontin prevented heart rhythm problems in research studies.
Is there a treatment for heart problems caused by fatty liver?
Currently, no specific osteopontin-blocking treatment exists for patients. However, proven treatments for fatty liver disease—weight loss, exercise, managing blood sugar and cholesterol—improve both liver and heart health. Research suggests osteopontin-targeting drugs could become available within 5-10 years after human trials.
How can I reduce my risk of heart rhythm problems if I have liver disease?
Focus on liver disease management: lose weight if overweight, exercise regularly, control blood sugar and cholesterol, and limit alcohol. These changes improve liver function and reduce inflammation throughout your body. Discuss heart monitoring with your doctor, especially if you experience palpitations or shortness of breath.
Should I get tested for atrial fibrillation if I have fatty liver disease?
Yes, discuss screening with your doctor. People with fatty liver disease have higher atrial fibrillation risk. Your doctor may recommend an EKG or heart monitoring, especially if you have symptoms like irregular heartbeats, chest discomfort, or shortness of breath during activity.
Want to Apply This Research?
- Track liver health markers (if available through your doctor) alongside heart rhythm symptoms. Log any episodes of heart palpitations, shortness of breath, or irregular heartbeats, and correlate them with weight changes and exercise patterns.
- Use the app to set and monitor goals for weight loss and regular aerobic exercise, as these improve both liver and heart health. Set reminders for medication adherence if prescribed for liver or heart conditions. Track meals to monitor sugar and fat intake, which directly affect liver health.
- Establish a baseline of heart rhythm symptoms and liver function tests with your doctor. Use the app to track these metrics monthly, noting any patterns with diet, exercise, or stress. Share this data with your healthcare provider during regular checkups to catch any progression early.
This research is from a preprint study in mice and observational human data, not yet confirmed by human clinical trials. The findings suggest osteopontin as a potential therapeutic target but do not establish proven treatments for patients. If you have fatty liver disease or heart rhythm concerns, consult your healthcare provider before making any medical decisions. Do not stop or change any prescribed medications based on this information. This article is for educational purposes and should not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.